there is little left for the people with HIV are able to receive the necessary treatment to control the virus that causes aids to through a patch. A new study published in "Nature Communications" shows an alternative to the pills. Researchers from the University of North Carolina at Chapel Hill (USA) have been working in an animal study to optimize an implant designed to inject drugs , which can be combined, and that is long-acting, in order to not only treat HIV infection but also prevent it.
"there is No technology approved or placed on the market by the FDA (health authorities and the U.S.) for the prevention of HIV long-term; we were the first to use this method of administration of multiple antiretroviral drugs", says Rahima Benhabbour, first author of the study. "Have a preventive treatment for HIV based on an injection once or twice a year would have an incredible impact to the patient."
In his opinion, "this technology not only holds promise for HIV, but for any type of infection that requires medication daily. We are talking of a safe injection, removable and durable".
The antiretroviral drugs are used in combination, both in prevention and in the treatment of HIV. The problem is that it is a treatment for life, and almost always should be taken every day.This technology is not only promising for HIV, but for any type of infection which requires a daily medication. We are talking of a safe injection, removable and durable
in Addition, in some countries of Sub-saharan africa, where HIV prevalence is highest , access to these medications it can be difficult to apart from that there is a lot of stigma associated with the virus.
"Because one of the major difficulties associated with the prevention of HIV is the lack of adhesion the pharmacological treatment, we wanted to create a medication administration system that essentially solve this problem," says senior author J. Victor Garcia.
The implant injection is composed of three elements: a solvent organic, a polymer, and the medication or medications that must be administered. The formulation results in a liquid similar to honey, which becomes solid when it is injected under the skin. The own combination determines over what period of time the drug will be released into the blood system.
In this study, we tested six antiretroviral drugs , and all maintained their physical and chemical properties within the development and at the time of its release. The six were also released from the implant at effective levels over a period of time sustained that varies from a month to a year.The own combination determines over what period of time the drug will be released into the blood system
The implant, injection drug created by the research team of the UNC is the first to address several drawbacks of the current method of supply of drugs of prolonged action for the HIV, i.e., the ability to delete it and quickly remove the presence of residual drugs in the system.
This is the first implant injection for HIV that can draw a week or after months of the injection. If it is not necessary to remove the implant biodegrades into lactic acid and glycolic acid, which are already found in the body and are absorbed easily.
The researchers plan to continue developing and improving this system of administration of multiple medications, observing their effects in relevant models in vivo and eventually in humans.The combination provides a ‘shield’ against HIV for 1 year or more, much longer than any antiretroviral now in the market
this is Not the first implant designed to manage anti-HIV drugs . In the past the International Conference on AIDS, held in Mexico City , Merck & Co. presented a small study of Pre-Exposure Prophylaxis (PrEP) that included only 12 people with an implant of slow release of an antiretroviral drug experimental designed to be durable in the body and prevent infection. The combination provides a ‘shield’ against HIV for 1 year or more, much longer than any antiretroviral now in the market.
The device, which is located in the first steps of research, released in the body in a progressive way the molecule is 'MK-8591 ', a potent new inhibitor that is currently in testing. In this randomized, double-blind, placebo-controlled phase 1, the researchers evaluated the effectiveness of placing patients 12 weeks for an implant with this compound or a placebo. According to their findings, 'MK-8591' was well tolerated and provided a level required to prevent infection during at least a year.Date Of Update: 25 September 2019, 06:03